CVRx, Inc. announced the enrollment of the first patient in the BENEFIT-HF trial, a major study testing Barostim therapy in a larger heart failure patient group. The trial will enroll 2,500 patients across 150 centers in the US and Germany, aiming to evaluate mortality and heart failure events. If successful, it could triple the eligible patient population for Barostim, broadening access to this FDA-approved neuromodulation device. The trial is expected to run through 2032, potentially strengthening Barostim's role in heart failure treatment.
YD Bio Limited's U.S. affiliate, EG BioMed US, has secured clinical lab licenses in Rhode Island and Pennsylvania, expanding its CLIA-certified, CAP-accredited lab's footprint to 46 states plus D.C. and Guam. This expansion enhances patient access to...
Vivani Medical's wholly owned subsidiary Cortigent will merge with Nasdaq-listed ClearOne, which will be renamed Cortigent Holdings and trade under the ticker CRGT. Vivani will own a majority stake in the combined company, which will focus on advanci...
Diffusion, a global communications agency, is growing its home and interiors portfolio by signing new clients including POVISON (furniture), LUSA Lighting, and Induction Hardware (appliances). The agency will support these premium brands with integra...
Heathrow Finance PLC announced a €350 million offering of 4-year senior secured notes with a stabilization period starting July 2, 2026, and ending by August 7, 2026. BNP Paribas and other major banks will manage the stabilization to support the bond...
Polibeli Group Ltd. has signed a non-binding Memorandum of Understanding with AUTHAIKAM COMPANY LIMITED to jointly evaluate a potential 100 MW AI computing center project in Thailand. The collaboration involves preliminary assessments such as site vi...
